Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today

Why Supernus Pharmaceuticals' Shares Plummeted 23.4% Today

After reporting disappointing interim news from its phase 3 study of SPN-810 as a treatment for aggressive impulses in ADHD patients, shares in Supernus Pharmaceuticals (NASDAQ: SUPN) tumbled 23.4% today.

Supernus Pharmaceuticals markets two commercial-stage epilepsy medicines, but a lot of investor's optimism has been tied instead to SPN-810, a drug that's being evaluated in two phase 3 trials for use in controlling aggressive impulses in ADHD patients.

IMAGE SOURCE: GETTY IMAGES.

Continue reading

Source: Fool.com